Connect with us

Health

New pancreatic cancer pill could reshape treatment as early trial results stun researchers

Published

on

New pancreatic cancer pill could reshape treatment as early trial results stun researchers

NEWYou can now listen to Fox News articles!

A new drug for pancreatic cancer is showing promise in early testing.

Advertisement

Daraxonrasib is a daily pill designed to block cancer signals linked to the RAS gene. It has now finished an early-stage clinical trial — the first time it was tested in people — to evaluate both its safety and effectiveness.

The clinical trial, led by the Dana-Farber Cancer Institute and published in The New England Journal of Medicine, tested the drug in 168 patients with advanced pancreatic cancer whose tumors had mutations in the RAS gene. All study participants had previously received at least one chemotherapy treatment.

6 THINGS TO KNOW ABOUT PANCREATIC CANCER AFTER FORMER SENATOR’S DIAGNOSIS

The drug is designed to block multiple active cancer signals that help tumor cells grow. This is especially important because more than 90% of pancreatic cancers carry these harmful mutations, researchers said.

Existing and older drugs that target RAS mutations only work on certain types that are uncommon in pancreatic cancer, such as KRAS mutations.

Advertisement

Daraxonrasib is a daily pill designed to block cancer signals linked to the RAS gene. It has now finished an early-stage clinical trial to evaluate its safety and effectiveness. (iStock)

At the 300-milligram dose — the amount that will be used in larger phase 3 trials — about 30% of patients saw a positive response, researchers noted. Overall, about 90% of patients had their cancer either shrink or stop getting worse.

DEADLY CANCER TYPE LINKED TO OBESITY AND HIGH STRESS LEVELS

There were some side effects reported — most commonly rash, mouth inflammation, nausea and diarrhea.

Lead investigator Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber, commented in a press release statement that this development could change the future of cancer care.

Advertisement

About 90% of patients treated with the drug experienced disease control, meaning their cancer was reduced or stabilized. (iStock)

“If supported by data from future clinical trials, daraxonrasib would be a targeted therapy relevant to nearly all patients with advanced pancreatic cancer,” he said.

RISK OF DEADLY CANCER TRIPLES WITH HIDDEN MOUTH BACTERIA, STUDY FINDS

“This trial provides the first published data showing the safety and broad activity of a RAS(ON) multi-selective inhibitor in pancreatic cancer,” Wolpin went on. “If it proves effective in larger clinical trials, it would signify a substantial shift in how this disease is treated.”

In an interview with Fox News Digital, the researcher claimed that daraxonrasib represents “one of the most promising therapy advances we’ve seen in pancreatic cancer.”

Advertisement

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

This is especially significant since pancreatic cancer has had “very few effective therapies” in the past, Wolpin noted.

“The study also showed disease control in approximately 90% of patients with metastatic pancreatic cancer, which is extremely exciting,” he added.

The study does not prove daraxonrasib is superior to standard treatment of chemotherapy, researchers noted. (iStock)

Wolpin noted that while side effects were common, most patients were able to tolerate treatment with “supportive care measures, and very few patients needed to stop therapy due to side effects.”

Advertisement

As this was a phase 1/2 study, it does not “definitively prove” the superiority of daraxonrasib compared to chemotherapy, Wolpin added.

CLICK HERE FOR MORE HEALTH STORIES

“The study did not include a randomized control arm that directly compared daraxonrasib with chemotherapy,” he said. “That being said, the results for daraxonrasib looked substantially better than what we have seen in prior clinical trials of chemotherapy in patients with previously treated metastatic pancreatic cancer.”

It also remains unclear how the drug may perform earlier in the disease, as the trial included patients who had already received prior treatments.

“Additional research is needed to determine how best to sequence or combine therapies to provide the most durable responses and cures,” the lead investigaror sid. (iStock)

Advertisement

For patients and families affected by pancreatic cancer, Wolpin noted that daraxonrasib signals “real momentum” toward effective treatments, but it is still investigational and is not a cure.

“Pancreatic cancer remains a challenging disease, and additional research is needed to determine how best to sequence or combine therapies to provide the most durable responses and cures,” he said.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Brian Slomovitz, director of gynecologic oncology and co-chair of the Cancer Research Committee at Mount Sinai Medical Center in Miami Beach, applauded this development in a separate interview with Fox News Digital.

“We are anxiously awaiting the upcoming plenary presentation of RASolute 302 at the ASCO meeting later this month,” said the expert, who was not involved in the study. “Greater than 90% of pancreatic cancers have activation of kRAS, which is a major factor in the development and progression of these cancers.” 

Advertisement

“Doubling the survival time in pretreated patients is unprecedented.”

“If the full dataset results that will be reported later this month confirm what was earlier released, I believe this will be one of the most important breakthroughs in all solid tumors,” Slomovitz went on. “Doubling the survival time in pretreated patients is unprecedented.”

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

The doctor added that the “magnitude of benefit” could “reshape the treatment landscape” and “establish a new standard of care.”

“We will need to evaluate the full dataset for efficacy and safety,” Slomovitz added. “I am more than cautiously optimistic, and I am truly excited for our patients and their families that suffer from this dreadful disease.”

Advertisement

Health

Deadly ‘fox tapeworm’ linked to lethal disease detected in West Coast wildlife

Published

on

Deadly ‘fox tapeworm’ linked to lethal disease detected in West Coast wildlife

NEWYou can now listen to Fox News articles!

A parasitic tapeworm known as Echinococcus multilocularis — often called the “fox tapeworm” — has been detected for the first time in West Coast wildlife. 

Advertisement

University of Washington researchers discovered the tapeworm, which can cause a rare but potentially deadly disease in humans, in 37 out of 100 coyotes sampled near Puget Sound in Washington State. The findings were published in PLOS Neglected Tropical Diseases earlier this year.

Researchers noted that the presence of the parasite in wildlife does not mean human infections are common, and that the risk to the general public remains low.

NEUROLOGISTS REVEAL THE TOP 3 FOODS TO AVOID TO PROTECT YOUR BRAIN AND NERVOUS SYSTEM

“The reason that [cases are] so high in coyotes is because they are regularly eating raw rodents, and that is the primary way for them to get infected,” said lead author Yasmine Hentati, who recently graduated from the UW with a doctorate in environmental and forest science, in a press release.

The study’s genetic testing showed the coyotes carried a newer, more infectious European variant that has become the predominant strain in the U.S. and Canada.

Advertisement

A parasitic tapeworm that causes echinococcosis — one of the most lethal human parasitic diseases — has been detected for the first time in West Coast wildlife.  (iStock)

Prior to the 2010s, the parasitic tapeworm was extremely rare in North America, with cases largely confined to the remote islands in Alaska, the authors said.

Over the last 15 years, the parasite has expanded its range, with dog and human infections increasing across the Midwestern U.S. and Canada, according to past reports.

5 OF THE TOP SOURCES OF FOODBORNE ILLNESS AND HOW TO PREVENT IT

Cases in coyotes have been spreading west from the upper Midwest for several years, and infected animals have been found on the West Coast, according to Dr. Linda Yancey, an infectious disease specialist at Memorial Hermann in the Houston area.

Advertisement

While Eastern Europe has some cases, the infection is very rarely seen in the U.S., Yancey noted.

University of Washington researchers discovered the tapeworm, known as Echinococcus multilocularis, in 37 out of 100 coyotes sampled near Puget Sound in Washington State. (iStock)

Most cases of echinococcosis are diagnosed in patients who immigrated from or traveled to Central and East Asia, the Middle East and North Africa.

“Worldwide, the area with the highest prevalence of human infections with the fox tapeworm is western China,” Yancey added.

How do humans get infected?

The tapeworm is transmitted among wild animals known as canids — typically cycling from foxes to rodents and back to foxes — and is often referred to as the “fox tapeworm,” Yancey told Fox News Digital.

Advertisement

Humans can get sick from accidentally ingesting worm eggs after handling contaminated soil or eating contaminated food. They can also get the infection by handling a pet that has the tapeworm and then touching their mouth, according to Cleveland Clinic.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Symptoms to watch for

The hallmark of the infection is fluid-filled sacs called cysts, which contain thousands of very small, immature tapeworms that develop commonly in the liver but can spread to other parts of the body, according to Cleveland Clinic.

The infection often goes undetected for years, or even decades, because the cysts grow at a very slow rate.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Advertisement

There are two main types of forms of the illness: cystic echinococcosis and alveolar echinococcosis, according to the Centers for Disease Control and Prevention. 

With cystic echinococcosis, cysts often develop in the liver and lungs. The body responds by building a protective wall around them as the cysts continue to grow slowly over years.

Symptoms can include abdominal pain or increased belly size (if it infects the liver) or coughing and shortness of breath (if the lungs are infected). (iStock)

Symptoms can include abdominal pain or increased belly size (if it infects the liver) or coughing and shortness of breath (if the lungs are infected). These signs usually do not appear until the cysts grow large enough to press on healthy organs and tissues, according to the CDC.

The infection becomes dangerous when a cyst ruptures — most often due to trauma — and may even lead to death if cyst fluid is released into the body.

Advertisement

CLICK HERE FOR MORE HEALTH STORIES

Alveolar echinococcosis is a rarer, more lethal form of the infection. It grows into a tumor-like mass that invades and destroys surrounding tissue, typically in the liver, but can also spread to other parts of the body, including the brain. In severe cases, it can lead to liver failure and death, experts say.

“Symptoms of liver failure include fatigue, yellowing of the skin and eyeballs, and abdominal pain,” Yancey cautioned.

This form of the infection can mimic cancer, so it’s important to see a doctor if symptoms are noticed, she added.

Prevention tips

While the overall risk of infection is low, simple precautions can further reduce exposure.

Advertisement

“The most important way to protect yourself from the fox tapeworm is also the simplest: good hand hygiene,” Yancey advised.

She recommends washing your hands before eating and after you have been outside or have handled soil in areas where the tapeworm is endemic.

The tapeworm is transmitted among wild animals known as canids — typically cycling from foxes to rodents and back to foxes. (iStock)

“For dog owners, prevent your animals from eating wild rodents and make sure all your pets get routine veterinary care,” Yancey added.

The CDC also recommends avoiding contact with wild animals that can carry the tapeworm, such as foxes, coyotes and stray dogs.

Advertisement

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“Routine testing and treatment for worms of all kinds keeps your pups healthy and [keeps] you safe,” Yancey noted.

Fox News Digital reached out to the lead authors of the study requesting comment.

Continue Reading

Health

One muscle protein may hold the key to staying stronger as you age, study finds

Published

on

One muscle protein may hold the key to staying stronger as you age, study finds

NEWYou can now listen to Fox News articles!

A newly identified muscle protein may help explain why people who stay active as they age often remain stronger and healthier for longer, according to new research.

Scientists found that a protein called NOX4 naturally declines with age and inactivity. As levels dropped, researchers observed signs of frailty, muscle loss, insulin resistance and liver disease in mice.

The findings were published in the journal Science Advances.

7 COMMON FITNESS MISTAKES OLDER ADULTS MAKE AND HOW TO AVOID THEM FOR BETTER WORKOUTS

Advertisement

Researchers believe NOX4 helps muscles repair themselves and adapt to the physical demands of exercise.

When NOX4 was removed from the muscles of mice, the animals became weaker, lost muscle mass and developed health problems commonly associated with aging.

Researchers found that declining levels of the muscle protein NOX4 with age and inactivity may contribute to weakness, muscle loss, and other health problems. (iStock)

The researchers also found that exercise helped restore NOX4 levels in older mice.

Josephine Hunt, an educational leader, former group fitness instructor and founder of The Resilience Revolution based in New Jersey, who was not involved in the study, told Fox News Digital that the findings help explain why exercise benefits so many aspects of health.

Advertisement

CLICK HERE FOR MORE HEALTH STORIES

“Movement is medicine,” Hunt said.

“The emerging NOX4 research is exciting because it helps explain something exercise scientists have observed for decades. Physical activity does far more than strengthen muscles.”

Researchers think NOX4 plays an important role in helping muscles recover and adjust to the stresses of exercise. (iStock)

Hunt said many people view exercise as a way to improve appearance or fitness, but its effects reach much deeper.

Advertisement

“Exercise appears to activate biological signaling pathways that help the body adapt, repair and become more resilient over time,” she said.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

She said one of the study’s biggest takeaways is that physical activity helps the body maintain its ability to recover from challenges.

“Exercise does not simply help us look younger or stay physically fit,” Hunt said. “It appears to help the body maintain its ability to adapt, repair and respond to stress.”

Experts say one of the study’s key findings is that physical activity helps the body preserve its ability to recover from challenges. (iStock)

Advertisement

Hunt added that healthy aging is about more than simply living longer.

“Healthy aging is not just about adding years to life,” she said. “It is about preserving strength, function, independence, cognitive health and overall quality of life.”

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Researchers stressed that additional studies are needed, but the findings may help explain why regular physical activity remains one of the most effective tools for maintaining health as people age.

The study was conducted in mice, meaning the findings do not necessarily translate directly to humans.

Advertisement

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

While the team also examined muscle samples from younger and older men and found similar declines in NOX4, additional research is needed to better understand the protein’s role in human aging.

Advertisement
Continue Reading

Health

Weekly weightlifting sweet spot may be linked to longer life, study finds

Published

on

Weekly weightlifting sweet spot may be linked to longer life, study finds

NEWYou can now listen to Fox News articles!

Sticking to a resistance or strength training routine for a certain amount of time may extend your life, according to a new study.

Research published in the British Journal of Sports Medicine analyzed whether workouts involving weightlifting and weight machines are linked to a lower risk of death over time.

The study followed more than 147,000 U.S. adults who participated in three large health studies spanning up to 30 years. More than 35,000 died during the study period.

THIS EXERCISE HABIT MAY SLASH DEMENTIA RISK AND HELP YOU LIVE LONGER, STUDY FINDS

Advertisement

Participants reported their exercise habits, including the number of minutes per week spent on resistance training and on aerobic activity, like walking, biking or swimming.

Resistance training levels were then compared with later death from any cause, as well as from cardiovascular disease, cancer, respiratory disease and neurological disease, according to a press release.

Doing a moderate amount of resistance training was linked with a lower risk of death in a recent study. (iStock)

Doing a moderate amount of resistance training was linked with a lower risk of death, according to study results. This outcome persisted even after researchers adjusted for other factors like age, smoking, diet quality, alcohol intake, family history and aerobic activity.

The clearest benefit was seen at around 90 to 119 minutes per week of resistance training.

Advertisement

EXERCISE PROGRAM REDUCES COMMON CANCER RECURRENCE AND BOOSTS SURVIVAL

People who stuck to this interval of training per week had a 13% lower risk of all-cause death, 19% lower risk of death from heart disease and 27% lower risk of death from neurological disease.

More than 120 minutes of resistance training per week did not appear to add extra benefit to the overall death risk, according to the findings.

The clearest benefit was seen at around 90 to 119 minutes per week of resistance training. (iStock)

A lower risk of cancer death was seen at even small amounts of resistance training — 30 to 59 minutes per week was associated with a 12% decreased risk.

Advertisement

The lowest overall death risk was found in people who did both higher aerobic activity and moderate to high resistance training.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

The study shows only an association between resistance training and lower death risk, not a direct cause, the researchers noted.

Other limitations were that participants reported their own exercise habits, which may not have been completely accurate, and the study did not measure how intensely they exercised.

30 to 59 minutes per week of strength training was associated with a 12% decreased risk of cancer death.

Advertisement

The authors reflected in the study that engaging in “sufficient aerobic or resistance training alone is linked to lower mortality, with a stronger effect from aerobic activity.”

CLICK HERE FOR MORE HEALTH STORIES

The lowest risk was seen among people who did high levels of both aerobic exercise and resistance training. However, for people already doing a very high amount of aerobic exercise (roughly five to six hours of jogging or 11 hours of brisk walking per week), adding resistance training did not appear to lower the risk any further, they noted.

The lowest overall death risk was found in people who did both higher aerobic activity and moderate to high resistance training. (iStock)

In a previous interview with Fox News Digital, Kenny Santucci, fitness trainer, gym owner and host of the “Strong New York” podcast, shared the importance of pairing general movement with a focus on muscle building.

Advertisement

For a better fitness outcome, Santucci encourages gym-goers to add more strength training to their routines and to lift “a little bit heavier.”

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“Strength training should be the basis of what you do,” he said. “I don’t have anything against cycling … but if you’re telling me that’s the basis of your training, and your goal is aesthetics, then you are not really helping yourself get to that point any easier.”

“Hard doesn’t necessarily mean it’s a better workout.”

Santucci recommends working at about 60% to 80% of capacity, pushing to a point of fatigue with moderate intensity.

Advertisement

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

“There’s a science behind muscle growth, and if there’s no external force pushing against the muscle tissue, and you’re not fueling yourself with protein, then you’re probably not going to build muscle,” he said.

“Hard doesn’t necessarily mean it’s a better workout … If you’re training at levels of intensity, then you’re reproducing good outcomes.”

Continue Reading
Advertisement

Trending